These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 30987998)

  • 1. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
    Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
    Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response.
    Mihanfar A; Asghari F; Majidinia M
    Mol Biol Rep; 2024 Mar; 51(1):474. PubMed ID: 38553623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
    Hu W; Lei L; Xie X; Huang L; Cui Q; Dang T; Liu GL; Li Y; Sun X; Zhou Z
    Cell Death Dis; 2019 Jul; 10(8):550. PubMed ID: 31320608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.
    Bakkenist CJ; Lee JJ; Schmitz JC
    Clin Colorectal Cancer; 2018 Dec; 17(4):255-257. PubMed ID: 30316683
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.
    Iwata T; Uchino T; Koyama A; Johmura Y; Koyama K; Saito T; Ishiguro S; Arikawa T; Komatsu S; Miyachi M; Sano T; Nakanishi M; Shimada M
    PLoS One; 2017; 12(5):e0178221. PubMed ID: 28558031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
    Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
    PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
    Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T
    J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
    Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
    Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status.
    Laroche-Clary A; Chaire V; Verbeke S; Algéo MP; Malykh A; Le Loarer F; Italiano A
    Sci Rep; 2020 May; 10(1):7488. PubMed ID: 32366852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.
    Lewis KA; Lilly KK; Reynolds EA; Sullivan WP; Kaufmann SH; Cliby WA
    Mol Cancer Ther; 2009 Apr; 8(4):855-63. PubMed ID: 19372558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
    Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
    Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.